Home
About
Overview
Sharing Data
ORCID
Help
History (5)
ASO Author Reflections: Bilateral Mastectomy After Neoadjuvant Therapy: An Ever-Increasing Trend?
Committee report: American Pediatrics: milestones at the millennium.
Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Anemia
Antineoplastic Combined Chemotherapy Protocols
Area Under Curve
Bayes Theorem
Benzimidazoles
Bile Duct Neoplasms
Breast Neoplasms
Carboplatin
Carcinoma, Hepatocellular
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Carcinoma, Transitional Cell
Cholangiocarcinoma
Deoxycytidine
Female
Gallbladder Neoplasms
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Humans
Induction Chemotherapy
Kidney Neoplasms
Kidney Pelvis
Liver Neoplasms
Lung Neoplasms
Maintenance Chemotherapy
Male
Maximum Tolerated Dose
Mesothelioma
Middle Aged
Nausea
Neoplasm Metastasis
Neutropenia
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Prostatic Neoplasms
Skin Neoplasms
Thrombocytopenia
Treatment Outcome
authors with profiles
Gini Fleming